WO2025240663 - USING CATEQUENTINIB WITH A SPECIFIC ADMINISTRATION REGIMEN FOR CANCER TREATMENT
National phase entry is expected:
Publication Number
WO/2025/240663
Publication Date
20.11.2025
International Application No.
PCT/US2025/029436
International Filing Date
14.05.2025
Title **
[English]
USING CATEQUENTINIB WITH A SPECIFIC ADMINISTRATION REGIMEN FOR CANCER TREATMENT
[French]
UTILISATION DE CATÉQUENTINIB AVEC UN RÉGIME D'ADMINISTRATION SPÉCIFIQUE POUR LE TRAITEMENT DU CANCER
Applicants **
ADVENCHEN PHARMACEUTICALS, LLC
Inventors
CHEN, Guoqing, Paul
CHEN, Judy
LI, Zhe
Priority Data
63/647,867
15.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1816 | |
| EPO | Filing, Examination | 14440 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 573 | |
| USA | Filing, Examination | 5480 |
Total:
22,898
Abstract[English]
The present invention provides a method of treating cancer in a subject comprising administering to the subject a regimen of catequentinib (AL3818) or its pharmaceutically acceptable salt for a treatment cycle, wherein the regimen is a daily administration of an amount of 6mg, 8mg, 10mg, 12mg, 14mg, 16mg, 18mg, 20mg, 22mg or 24mg catequentinib, or its pharmaceutically acceptable salt for 3, 4, 5, or 6 days out of 7 days.[French]
La présente invention concerne une méthode de traitement du cancer chez un sujet comprenant l'administration au sujet d'un régime de catéquentinib (AL3818) ou de son sel pharmaceutiquement acceptable pour un cycle de traitement, le régime étant une administration quotidienne d'une quantité de 6 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 18 mg, 20 mg, 22 mg ou 24 mg de catéquentinib, ou son sel pharmaceutiquement acceptable pendant 3, 4, 5 ou 6 jours sur 7.